Literature DB >> 30108855

Design, facile synthesis and anthelmintic activity of new O-substituted 6-methoxybenzothiazole-2-carbamates. Part II.

A Mohsen M E Omar1, Omaima M Aboulwafa1, Doaa A E Issa1,2, Mai S M El-Shoukrofy1, May E Amr1, Ibrahim M El-Ashmawy3.   

Abstract

In the framework of pursuing the design and synthesis of a new series of substituted 6-methoxybenzothiazole-2-carbamates as potential anthelmintics, and as a continuation of the expended efforts in part I, we have set out to develop novel compounds with enhanced anthelmintic activity by blocking the 6-position of benzothiazole with side chains of different polarities. Guided by the findings in part I, and reporting the paramphistomicidal activity of oxadiazoline derivatives V and VI, we aimed to synthesize target benzothiazoles designed to comprise some planar heterocyclic ring systems, namely, 1,3,4-oxadiazoles and 1,2,4-triazoles, bearing a variety of hydrophobic and hydrophilic components. The synthesis of the desired compounds was primarily achieved by cyclization of 6-acetohydrazide, 1. The in vitro paramphistomicidal activity of all synthesized carbamates was evaluated. Four synthesized carbamates exhibited notable activity. Compound 24, methyl 6-[(5-(4-bromophenacylsulfanyl)-[1,3,4]-oxadiazol-2-yl)methoxy]benzothiazole-2-carbamate, displayed an equipotent effect to the reference drug oxyclozanide at a concentration of 80 μg mL-1; compounds 9, 10 and 23 showed high orders of anthelmintic effect. A structural computational study on the polar nature and hydrophilic-lipophilic properties of the synthesized carbamates was undertaken to discuss their structure-activity relationship (SAR). Besides, pharmacophore mapping was performed using eight active compounds as a training set. The generated pharmacophore model revealed five common features and was validated using fenbendazole, triclabendazole and triclabendazole sulfoxide.

Entities:  

Year:  2017        PMID: 30108855      PMCID: PMC6072514          DOI: 10.1039/c7md00140a

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  6 in total

1.  Cyclization of some carbothioamide derivatives containing antipyrine and triazole moieties and investigation of their antimicrobial activities.

Authors:  Hacer Bayrak; Ahmet Demirbas; Neslihan Demirbas; Sengül Alpay Karaoglu
Journal:  Eur J Med Chem       Date:  2010-08-19       Impact factor: 6.514

2.  Chemotherapy of paramphistomosis in sheep.

Authors:  P F Rolfe; J C Boray
Journal:  Aust Vet J       Date:  1988-05       Impact factor: 1.281

3.  Synthesis and anti-inflammatory evaluation of some condensed [4-(3,4-dimethylphenyl)-1(2H)-oxo-phthalazin-2-yl]acetic acid hydrazide.

Authors:  Mosaad S M Abd Alla; Mohamed I Hegab; Nageh A Abo Taleb; Sherifa M Hasabelnaby; A Goudah
Journal:  Eur J Med Chem       Date:  2009-10-23       Impact factor: 6.514

4.  Structure-activity relationships of benzothiazole and benzimidazole anthelmintics: a molecular modeling approach to in vivo drug efficacy.

Authors:  R O McCracken; K B Lipkowitz
Journal:  J Parasitol       Date:  1990-12       Impact factor: 1.276

5.  Synthesis and biological evaluation of new 2,3-dihydrothiazole derivatives for antimicrobial, antihypertensive, and anticonvulsant activities.

Authors:  A M Omar; N H Eshba
Journal:  J Pharm Sci       Date:  1984-08       Impact factor: 3.534

6.  Design, facile synthesis and anthelmintic activity of new O-substituted 6-methoxybenzothiazole-2-carbamates. Part II.

Authors:  A Mohsen M E Omar; Omaima M Aboulwafa; Doaa A E Issa; Mai S M El-Shoukrofy; May E Amr; Ibrahim M El-Ashmawy
Journal:  Medchemcomm       Date:  2017-05-12       Impact factor: 3.597

  6 in total
  1 in total

1.  Design, facile synthesis and anthelmintic activity of new O-substituted 6-methoxybenzothiazole-2-carbamates. Part II.

Authors:  A Mohsen M E Omar; Omaima M Aboulwafa; Doaa A E Issa; Mai S M El-Shoukrofy; May E Amr; Ibrahim M El-Ashmawy
Journal:  Medchemcomm       Date:  2017-05-12       Impact factor: 3.597

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.